Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors

Leukemia and Lymphoma

Volumn 52, Issue 9, 2011, Pages 1623-1625

  Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; FLUDARABINE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PREDNISONE; REACTIVE OXYGEN METABOLITE; RITUXIMAB; STRESS ACTIVATED PROTEIN KINASE; VINCRISTINE; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; CUTANEOUS T CELL LYMPHOMA; DNA DAMAGE; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; HEMATOLOGIC MALIGNANCY; HUMAN; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NOTE; OXIDATIVE STRESS; PRIORITY JOURNAL; WALDENSTROEM MACROGLOBULINEMIA;

APOPTOSIS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; STRESS, PHYSIOLOGICAL; WALDENSTROM MACROGLOBULINEMIA;

EID: 80052062789     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.573890     Document Type: Note

References (20)

1. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-784. (Pubitemid 44348499)
2. Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat Rev Drug Discov 2007;6:1-2.
3. Badros AZ, Philip R, Niesvizk R, et al. Phase I trial of vorinostat plus bortezomib (bort) in relapsed/refractory multiple myeloma (mm) patients. J Clin Oncol 2008;26(15 Suppl.): Abstract 8548.
4. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-1331.
5. Dai Y, Rahmani M, Dent P, Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 Activation. Mol Cell Biol 2005;25:5429-5444. (Pubitemid 40853579)
6. Merchionne F, Procaccio P, Dammacco F. Waldenstrom's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center. Crit Rev Oncol Hematol 2010 Oct 28. [Epub ahead of print]
7. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007;13:3320-3325. (Pubitemid 46944918)
8. Sun JY, Tseng H, Xu L, et al. Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenstró m macroglobulinemia cells. Leuk Lymphoma 2011;52:1777-1786.
9. Catley L, Weisberg E, Tai YT, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003;102:2615-2622. (Pubitemid 37193603)
10. Lucas DM, Alinari L, West DA, et al. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One 2010;5:e10941.
11. Vrana JA, Decker RH, Johnson CR, et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999;18:7016-7025. (Pubitemid 30028872)
12. Fotheringham S, Epping MT, Stimson L, et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 2009;15:57-66.
13. Rao R, Nalluri S, Fiskus W, et al. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplas-mic reticulum stress in mantle cell lymphoma cells. Clin Cancer Res 2010;16:4742-4754.
14. Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoyla-nilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001;98:10833-10838. (Pubitemid 32878706)
15. Rosato RR, Kolla SS, Hock SK, et al. Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. J Biol Chem 2010;285:10064-10077.
16. Manion MK, Fry J, Schwartz PS, Hockenbery DM. Small-molecule inhibitors of Bcl-2. Curr Opin Investig Drugs 2006;7:1077-1084. (Pubitemid 44941752)
17. Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005;102:8567-8572. (Pubitemid 40862776)
18. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003; 102:3765-3774. (Pubitemid 37409399)
19. Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006;108: 3441-3449.
20. Dai Y, Chen S, Kramer LB, Funk VL, Dent P, Grant S. Interactions between bortezomib and romidepsin and belino-stat in chronic lymphocytic leukemia cells. Clin Cancer Res 2008;14:549-558. (Pubitemid 351226125)